$XBI $136 +1.0%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$MRNA -0.2% Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States. source
$OCGN -28.1% Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate. source
$BNTX -0.7% & PFE +2.2% Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations. source
Pipeline Updates
$HRMY -0.4% Harmony Biosciences Presents New Analysis Demonstrating The Clinical Impact Of WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting. source
$TMDX +1.1% TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting. source
$ADMS +5.8% New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease. source
$IBRX -3.1% ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients. source
$VERU -1.3% Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer. source
$ETNB +1.4% 89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the Treatment of NASH. source
$CASI +0.6% CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma. source
$CUE +3.5% Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC. source
$VOR +6.8% Vor to Develop Multi-Targeted CAR-Ts with Abound Bio. source
$EQ -2.0% Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry. source
$OYST +2.0% Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases. source
$ALXO +1.8% ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer. source
$GKOS 0% Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR. source
$MNKD -1.2% MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases. source
$OBSV +4.3% ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021. source
$INRLF +0.9% Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate. source
$MDWD +14.3% MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study. source4
$PRTA +14.3% Prothena to Participate in JMP Securities Life Sciences Conference on June 16. source
$ANVS +12.1% On 6/8 Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study. source4htbx
$HTBX +40.2% HS-110 favorable survival data reported at ASCO2021. source
Financial Updates
$VRNA +13.2% Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China. source
$ORPH +302.3% Orphazyme and CytRx skyrocket ahead of FDA decision on Arimoclomol. source
$CYTR +55.0% Orphazyme and CytRx skyrocket ahead of FDA decision on Arimoclomol. source
$HEPA +15.3% Hepion Pharmaceuticals to be Added to the Russell Microcap® Index. source
$AXLA +48.7% AXA1125 trial initiating in June. source
$GLTO +60% Galecto Hosted Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments on 6/9/21. source
Posted by FS